|Articles|October 1, 2002

Commitment to R&D strengthens Allergan product pipeline

Irvine, CA-When Allergan announced in January that it planned to spin off its optical medical device business into a separate company called Advanced Medical Optics (AMO), David E.I. Pyott, chairman, president, and CEO of Allergan, said the company would evolve into a specialty pharmaceutical company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME

Video

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

SriniVas R. Sadda, MD, FARVO; Hong-Uyen Hua, MD; Adrienne W. Scott, MD, FASRS

Commitment to R&D strengthens Allergan product pipeline

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

Why aren’t there enough ophthalmologists?

Root cause–based dry eye classification and the shift toward precision medicine

Refractive cataract surgery: aiming for '20/happy' patients

Bausch + Lomb survey ties dry eye symptom relief to quality of life gains

Latest CME

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

EyeCon 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Trending on Eye Care Network - Ophthalmology Times

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data